Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist clinically approved for type 2 diabetes and obesity management, has demonstrated pleiotropic effects in preclinical NAFLD models. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.